之江生物(688317) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥32,134,673.50, a decrease of 37.27% compared to ¥51,227,345.41 in the same period last year[4] - The net profit attributable to shareholders was -¥16,017,333.00, representing a decline of 159.53% from ¥26,906,914.34 year-on-year[4] - The net cash flow from operating activities was ¥2,001,042.18, down 87.71% from ¥16,281,139.42 in the previous year[4] - Basic and diluted earnings per share were both -¥0.08, a decrease of 157.14% compared to ¥0.14 in the previous year[4] - The total comprehensive income for Q1 2025 was CNY -16,031,288.73, compared to CNY 21,748,318.98 in Q1 2024[18] - Net profit for Q1 2025 was a loss of CNY 16,017,333.00, compared to a net profit of CNY 26,906,914.34 in Q1 2024, indicating a substantial decline[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,773,525,157.93, a slight decrease of 0.43% from ¥3,789,950,091.12 at the end of the previous year[5] - The company's current assets totaled RMB 2,931,380,855.10, showing a marginal decrease from RMB 2,935,605,773.60 in the previous period[12][14] - The total liabilities increased to RMB 241,718,617.69 from RMB 153,063,328.61, indicating a significant rise in financial obligations[14] - The company's equity attributable to shareholders decreased to RMB 3,531,806,540.24 from RMB 3,636,886,762.51, reflecting a decline in shareholder value[14] Cash Flow - Cash flow from operating activities generated a net cash inflow of CNY 2,001,042.18 in Q1 2025, down from CNY 16,281,139.42 in Q1 2024[22] - Cash flow from investing activities showed a net outflow of CNY 151,122,626.55 in Q1 2025, compared to a net outflow of CNY 13,028,214.97 in Q1 2024[23] - Cash flow from financing activities resulted in a net inflow of CNY 9,581,832.13 in Q1 2025, contrasting with a net outflow of CNY 13,443,528.37 in Q1 2024[23] Research and Development - Research and development expenses totaled ¥13,572,425.59, an increase of 11.75% compared to ¥12,145,804.86 last year, accounting for 42.24% of operating revenue[5] - The company reported a significant increase in research and development expenses to CNY 13,572,425.59 in Q1 2025 from CNY 12,145,804.86 in Q1 2024[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 15,832[9] - The company has a total of 7,493,674 shares repurchased, representing 3.90% of the total shares outstanding as of March 31, 2025[10] - The company has not reported any significant changes in shareholder participation in margin trading or securities lending activities[11] Inventory and Receivables - Accounts receivable decreased to RMB 47,919,007.69 from RMB 55,019,022.02, indicating a reduction in outstanding customer payments[12] - Inventory levels decreased to RMB 50,647,478.79 from RMB 57,369,192.76, suggesting improved inventory management[12] Revenue and Costs - Total operating costs increased significantly to CNY 51,227,131.69 in Q1 2025 from CNY 17,171,479.82 in Q1 2024, representing a rise of 198.5%[17] - The decline in revenue and profit was primarily attributed to a decrease in product sales and prices[7]